New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2013
08:39 EDTABMDAbiomed strength should be used as a selling opportunity, says Northland
Northland Securities recommends using any strength today as a selling opportunity and said the FDA close-out letter has nothing to do with the Department of Justice/Hippa investigation on off-label marketing. Shares are Underperform rated with a $9 price target.
News For ABMD From The Last 14 Days
Check below for free stories on ABMD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
08:05 EDTABMDAbiomed acquires exclusive license for Opsens' optical sensor technology
Abiomed announced its acquisition of an exclusive license from collaboration partner Opsens. Through this exclusive licensing agreement, which covers the use of certain optical sensor technology in the field of cardio-circulatory assist devices, Opsens' miniature optical pressure sensors will be integrated into the Impella heart pump catheters to help further automate the control and operation of the Impella device in the catheterization lab. This licensing agreement, which secures Abiomed's rights to the technology and gives Abiomed the right to manufacture the sensors, is a continuation of an initial collaboration, entered into between Opsens and Abiomed in 2010.
April 10, 2014
07:34 EDTABMDAbiomed shares attractive following recent weakness, says Stephens
Stephens believes Abiomed shares are attractively valued following their recent weakness given the stock's valuation relative to peers. The firm says Abiomed remains one of its top ideas and reiterates its Overweight rating and $34 price target on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use